ABSCINT is a belgian clinical-stage molecular imaging company that develops radiopharmaceutical diagnostics to guide patients and physicians to the right treatment at the right time.
At Trasis, we are convinced that the technologies developed by this company will contribute to the development of a better quality of life and increasingly effective patient management. This is why we have decided to support Abscint by sharing our acquired expertise and to co-invest in the development of this innovative startup. Beyond the solutions we offer, we also want to invest in the value chain of radiopharmacy and digital imaging.

Fore more information, download the press release

Trasis co-invests and supports the development of Abscint